Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16206206 | 0.84 | HRH4 (0.43) | HRH4HRH3DPP4GABRA2GABRB2 | |
| SCHEMBL16263166 | 0.84 | AR (0.41) | HRH4HRH3DPP4SMPD1MDM4 | |
| SCHEMBL18367570 | 0.84 | HRH4 (0.43) | HRH4HRH3DPP4GABRA2GABRB2 | |
| SCHEMBL18367607 | 0.84 | HRH4 (0.43) | HRH4HRH3DPP4GABRA2GABRB2 | |
| SCHEMBL12432229 | 0.81 | HRH4 (0.46) | HRH4HRH3DPP4GABRA2GABRB2 | |
| SCHEMBL21324874 | 0.80 | HRH4 (0.50) | HRH4HRH3DPP4GABRA2GABRB2 | |
| SCHEMBL18367572 | 0.79 | HRH4 (0.45) | HRH4HRH3DPP4GABRA2GABRB2 | |
| SCHEMBL12247032 | 0.78 | HRH4 (0.59) | HRH4HRH3DPP4GABRA2GABRB2 | |
| SCHEMBL12247028 | 0.78 | HRH4 (0.59) | HRH4HRH3DPP4GABRA2GABRB2 | |
| SCHEMBL12392028 | 0.78 | HRH4 (0.51) | HRH4HRH3DPP4GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167149-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230147962-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2023-05-11 | — | — | US | disclosed |
| WO-2023065137-A1 | SITE-SPECIFIC GLYCOPROTEIN CONJUGATES AND METHODS FOR MAKING THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-04-27 | — | — | WO | disclosed |
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-09-30 | — | — | US | disclosed |
| US-10316017-B2 | COT modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190023732-A1 | OLIGONUCLEOTIDES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-01-24 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| US-9527853-B2 | Fused triazole derivatives as gamma secretase modulators | ARES TRADING S.A. (CH) | 2016-12-27 | — | — | US | disclosed |
| US-20150183790-A1 | FUSED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | MERCK PATENT GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-20120142711-A1 | ACID-LABILE TRIGGER UNITS | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | HRH4 2806/4885HRH3 2884/4885DPP4 3764/4885 |
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC7, SIGLEC9, CD47 | HRH4 3420/4885HRH3 2507/4885DPP4 3572/4885 |
| US-10316017-B2 | COT modulators and methods of use thereof | BRDT, THRB, HCCS | HRH4 2806/4885HRH3 2884/4885DPP4 3764/4885 |
| US-20120142711-A1 | ACID-LABILE TRIGGER UNITS | ASIC1, ABL1, CA9 | HRH4 59/4885HRH3 38/4885DPP4 573/4885 |
| US-20150183790-A1 | FUSED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, GSAP, BACE2 | HRH4 2422/4885HRH3 2102/4885DPP4 711/4885 |
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | FUT5, FUT6, SIGLEC7 | HRH4 4122/4885HRH3 3740/4885DPP4 1827/4885 |
| US-20230167149-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC7, SIGLEC9, ASGR1 | HRH4 3304/4885HRH3 2198/4885DPP4 3406/4885 |
| US-20190023732-A1 | OLIGONUCLEOTIDES | NSUN3, DCLRE1B, TRDMT1 | HRH4 4355/4885HRH3 4109/4885DPP4 348/4885 |
| US-20230147962-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | FAP, FIBP, FGFR1 | HRH4 2429/4885HRH3 2865/4885DPP4 1126/4885 |
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | FCER2, SQLE, TTL | HRH4 305/4885HRH3 770/4885DPP4 1276/4885 |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | HRH4 2806/4885HRH3 2884/4885DPP4 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.